We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Imaging Reveals New Pathway for Anti-Cancer Treatment

By Biotechdaily staff writers
Posted on 22 May 2008
Researchers have discovered a possible new pathway for anti-tumor drugs to kill cancer cells and proposed how to improve the design of tiny drug-delivery particles for use in "nanomedicine.”

The synthetic "polymer micelles” are drug-delivery spheres 60-100 nanometers in diameter, or about 100 times smaller than a red blood cell. More...
The spheres contain drugs in their inner core and contain an outer shell made of a material called polyethylene glycol.

Researchers showed for the first time how this shell of polyethylene glycol latches onto the membranes of cancer cells, allowing fluorescent probes mimicking cancer drugs to enter the cancer cells, according to Dr. Ji-Xin Cheng, an assistant professor in the Weldon School of Biomedical Engineering and department of chemistry at Purdue University (West Lafayette, IN, USA). "This is an interesting new step in developing nanomedicine techniques in drug delivery,” he said.

The research is being led by Dr. Cheng and Dr. Kinam Park, a professor of biomedical engineering and pharmaceutics. New findings are detailed in two research articles. One study was published in the May 6, 2008 issue of the Proceedings of the [U.S.] National Academy of Sciences (PNAS), and another study was published in the May 2008 issue of the journal Langmuir.

The researchers utilized an imaging technique called Förster resonance energy transfer imaging (FRET) to make two significant findings: how fluorescent molecules mimicking the cancer drug paclitaxel enter tumor cells and how the micelles break down in the blood before they have an opportunity to deliver the drug to cancer cells.

An important feature of micelles is that they combine two types of polymers, one being hydrophobic, and the other hydrophilic, meaning they are either unable or able to mix with water. The hydrophobic core was loaded with a green dye and the hydrophilic part labeled with a red dye.

Experiments demonstrated that "core-loaded” fluorescent molecules mimicking the drug entered cancer cells within 15 minutes, suggesting a new drug-delivery pathway to destroy tumor cells, according to Dr. Cheng. The fluorescent probes produced a green color on the membranes and a yellowish color inside the cells. "So this technique provides a system to monitor in real time how well anti-cancer drug delivery is working,” Dr. Cheng said.

Further findings made by the investigators using mice demonstrate specifically how the drug is released prematurely in the blood. "We first proved that micelles are unstable in the blood, and then we answered why they don't remain intact,” Dr. Cheng said.

The researchers also propose a possible way to correct the problem by "crosslinking,” or reinforcing polymer strands in the micelles with chemical bonds made of two sulfur atoms. This reinforced structure might remain intact in the blood long enough to deliver the micelles to tumor sites, where they would biodegrade, according to Dr. Cheng.

The researchers are the first to use FRET to study drug release from polymer micelles into a tumor cell. Because micelles remain intact in water, researchers had thought the particles were stable in blood, but Canadian scientists in 2003 showed that the micelles are quickly broken down, releasing the drug into the blood. "The reason is very simple,” Dr. Cheng said. "Unlike water, blood has many components like surfactants and lipids and proteins that interact with the whole micelle structure. As a result, the micelles are unstable in blood and the drug is released too soon.”

The Purdue researchers evaluated how stable micelles are in different blood components. Findings indicated that the micelles remained intact in red blood cells and components of blood plasma except for a class of plasma proteins called alpha and beta globulins, which caused the drug to be released. "There could also be other blood components that cause the drug to be released, but our proposal of using crosslinking could prevent this from happening,” Dr. Cheng said.

Future study, according to the researchers, may concentrate on creating micelles that remain intact longer in the blood by using crosslinking.


Related Links:
Purdue University

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.